Jennifer Jarrett sold $954k of RCUS
Chief Operating Officer at Arcus Biosciences, Inc.. 50,291 shares at an average of $18.97, traded Nov 7, 2025, filed Nov 12, 2025.
Score components
- +20RoleCOO
- +24Trade size$954k at market
- +5Share of holdings soldSold 19% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.6%, 3m +6.8%, 6m +25.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001671311-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | MOption exercise Common Stock10b5-1 | +50,291 | $1.23 | $62k | 264,523 | Nov 12, 2025 |
| Nov 7, 2025 | SOpen-market sale Common Stock10b5-1 | -50,291 | $18.97 | $954k | 214,232 | Nov 12, 2025 |
| Nov 7, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,291 | $1.23 | $62k | 80,583 | Nov 12, 2025 |
Related signals
Other insiders at Arcus Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Arcus Biosciences, Inc. | Alexander Azoy Chief Accounting Officer | $85k 2,827 shares | -7% | |
| 25Weak | Arcus Biosciences, Inc. | Juan C. Jaen President | $2.0M 68,569 shares | -8% | |
| 23Weak | Arcus Biosciences, Inc. | Juan C. Jaen President | $878k 31,431 shares | -3% | |
| 3Weak | Arcus Biosciences, Inc. | Alexander Azoy Chief Accounting Officer | $66k 2,562 shares | -6% | |
| 14Weak | Arcus Biosciences, Inc. | Robert C. Goeltz II Chief Financial Officer | $199k 7,763 shares | -8% | |
| 29Weak | Arcus Biosciences, Inc. | Juan C. Jaen President | $681k 31,823 shares | -3% | |
| 21Weak | Arcus Biosciences, Inc. | Robert C. Goeltz II Chief Financial Officer | $153k 6,552 shares | -9% | |
| 45Moderate | Arcus Biosciences, Inc. | Terry J Rosen Chief Executive Officer | $1.2M 54,691 shares | -2% | |
| 32Weak | Arcus Biosciences, Inc. | Juan C. Jaen President | $467k 21,208 shares | -6% | |
| 36Weak | Arcus Biosciences, Inc. | Robert C. Goeltz II Chief Financial Officer | $279k 12,662 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.